Author/Authors :
Slack-Davis، نويسنده , , Jill and DaSilva، نويسنده , , John O. and Parsons، نويسنده , , Sarah J.، نويسنده ,
Abstract :
In this issue of Cancer Cell, Carretero and colleagues report that Src and FAK signaling pathways are activated in lung cancers when the tumor suppressor LKB1 is deleted. These findings suggest the use of unique combinatorial therapies for treatment of lung cancers.